Emergency vasoactive drug infusions (vasopressors, inotropes, and vasodilators) are a cornerstone of haemodynamic resuscitation in critically ill patients with distributive, cardiogenic, or vasodilatory shock. These medications are administered as continuous intravenous infusions titrated to physiological targets — most commonly mean arterial pressure (MAP) ≥65 mmHg, cardiac index ≥2.2 L/min/m², or organ-specific perfusion markers. Each vasoactive agent has distinct receptor pharmacology: alpha-1 adrenergic stimulation produces vasoconstriction; beta-1 adrenergic stimulation produces positive inotropy and chronotropy; beta-2 stimulation produces vasodilation and bronchodilation; dopaminergic (DA) stimulation produces renal and splanchnic vasodilation. The selection, dosing, and titration of these agents requires understanding of their receptor profiles, dose-response relationships, and organ-specific effects. Key agents and dose ranges are: norepinephrine 0.01–3.3 mcg/kg/min (first-line vasopressor in septic shock); dopamine 2–20 mcg/kg/min (dose-dependent receptor profile); dobutamine 2.5–20 mcg/kg/min (primary inotrope in cardiogenic shock); vasopressin 0.03–0.04 units/min fixed dose (non-catecholamine vasopressor); epinephrine 0.01–1 mcg/kg/min (anaphylaxis, cardiac arrest, refractory shock); phenylephrine 0.5–8 mcg/kg/min (pure alpha-1 vasopressor, useful when tachycardia is problematic). These infusions are usually administered via central venous access using syringe pumps or volumetric pumps with concentration-based programming to minimise dosing errors.
Infusion rate (mL/h) = [Dose (mcg/kg/min) × Weight (kg) × 60] ÷ Concentration (mcg/mL); Norepinephrine: 0.01–3.3 mcg/kg/min; Dopamine: 2–20 mcg/kg/min; Dobutamine: 2.5–20 mcg/kg/min; Vasopressin: 0.03–0.04 units/min (fixed, not weight-based); Epinephrine: 0.01–1 mcg/kg/min; Phenylephrine: 0.5–8 mcg/kg/min
- 1Identify the shock phenotype: distributive/vasodilatory shock (septic, anaphylactic, neurogenic) — requires vasopressors (norepinephrine first-line); cardiogenic shock — requires inotropes (dobutamine) ± vasopressors; hypovolaemic shock — fluid resuscitation first, vasopressors only if refractory.
- 2Establish central venous access (CVC or intraosseous if emergent) before initiating vasopressors; norepinephrine and phenylephrine may cause tissue necrosis if extravasated from a peripheral IV — limit peripheral administration to short durations in life-threatening situations only.
- 3Prepare the drug at a standard concentration using your institution's drug library or standardised protocols; common concentrations: norepinephrine 4–8 mg in 250 mL (16–32 mcg/mL); dopamine 400 mg in 250 mL (1600 mcg/mL); dobutamine 250 mg in 250 mL (1000 mcg/mL).
- 4Calculate initial infusion rate using: Rate (mL/h) = [Dose (mcg/kg/min) × Weight (kg) × 60] ÷ Concentration (mcg/mL); start at the low end of the dose range and titrate every 5–15 minutes to haemodynamic targets.
- 5Set physiological targets before initiating infusions: MAP ≥65 mmHg in most septic shock patients (individualise for hypertensive patients to MAP ≥70–80 mmHg); urine output ≥0.5 mL/kg/h; lactate clearance >10% every 2 hours.
- 6Monitor for agent-specific adverse effects: tachycardia and arrhythmias (dopamine > epinephrine > dobutamine); digital/mesenteric ischaemia at high vasopressor doses; catecholamine-induced cardiomyopathy with prolonged high-dose epinephrine; hyponatraemia and water retention with vasopressin.
- 7Plan vasopressor weaning once haemodynamic stability is achieved: reduce dose by 25–50% every 30–60 minutes while monitoring for clinical deterioration — avoid abrupt discontinuation which can cause rebound hypotension.
Norepinephrine is the first-line vasopressor for septic shock (Surviving Sepsis Campaign 2021).
At 13.1 mL/h delivering 0.1 mcg/kg/min, this dose is in the low-to-moderate range; titrate upward in 0.05 mcg/kg/min increments every 5–15 minutes to MAP target.
The 'renal dose dopamine' concept (2–3 mcg/kg/min for renoprotection) is no longer supported by evidence.
At 2–5 mcg/kg/min, dopamine primarily stimulates dopaminergic and beta-1 receptors (inotropy, mild chronotropy); at 5–10, beta-1 predominates; at >10 mcg/kg/min, alpha-1 vasconstriction predominates with significant tachyarrhythmia risk.
Vasopressin is always given at a fixed dose (0.03–0.04 units/min) — it is not titrated like catecholamines.
Adding vasopressin as an adjunct 'catecholamine-sparing' agent allows norepinephrine dose reduction, potentially reducing catecholamine-related adverse effects. The VASST trial demonstrated no mortality benefit of vasopressin over norepinephrine alone but supported its safety.
Dobutamine improves cardiac output via beta-1 inotropy but can cause tachycardia and vasodilation — add norepinephrine if BP falls.
Dobutamine is the primary inotrope in cardiogenic shock; titrate to clinical response (improved cardiac output, urine output, lactate clearance) rather than to a fixed dose. Doses >20 mcg/kg/min rarely provide additional benefit.
Primary care physicians and internists use Emergency Drug Drips during routine clinical assessments to screen patients, establish baselines for longitudinal monitoring, and identify individuals who may need referral to specialists for further diagnostic evaluation or therapeutic intervention.
Hospital clinical pharmacists apply Emergency Drug Drips to verify drug dosing calculations, particularly for medications with narrow therapeutic indices like warfarin, aminoglycosides, and chemotherapy agents where patient-specific factors such as renal function and body weight critically affect safe dosing ranges.
Public health epidemiologists use Emergency Drug Drips in population-level screening programs to calculate disease prevalence, assess screening test sensitivity and specificity, and determine the number needed to screen to detect one case in various demographic subgroups.
Clinical researchers incorporate Emergency Drug Drips into study design protocols to calculate sample sizes, determine statistical power for detecting clinically meaningful differences, and establish inclusion criteria based on quantitative physiological thresholds.
Pediatric versus adult reference ranges
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in emergency drug drips calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Pregnancy and hormonal variations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in emergency drug drips calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Extreme body composition
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in emergency drug drips calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Methylene blue for vasoplegic syndrome
Vasoplegic syndrome (catecholamine-refractory vasodilation post-cardiac surgery or severe sepsis) may respond to methylene blue 1.5–2 mg/kg IV bolus, which inhibits nitric oxide synthase and guanylate cyclase — reversing pathological vasodilation. Methylene blue is a rescue agent for refractory vasoplegia not responsive to conventional vasopressors.
| Drug | Receptors | Dose Range | Primary Use |
|---|---|---|---|
| Norepinephrine | α1 ++ β1 + | 0.01–3.3 mcg/kg/min | First-line vasopressor: septic/distributive shock |
| Dopamine | DA β1 α1 (dose-dependent) | 2–20 mcg/kg/min | Second-line vasopressor; some bradycardia indications |
| Dobutamine | β1 ++ β2 + | 2.5–20 mcg/kg/min | Cardiogenic shock; low cardiac output states |
| Vasopressin | V1 (smooth muscle) | 0.03–0.04 units/min (fixed) | Adjunct vasopressor; catecholamine-sparing |
| Epinephrine | β1 β2 α1 (all) | 0.01–1 mcg/kg/min | Anaphylaxis; cardiac arrest; refractory shock |
| Phenylephrine | α1 only | 0.5–8 mcg/kg/min | Pure vasopressor; tachycardia-sensitive patients |
Why is norepinephrine preferred over dopamine in septic shock?
The SOAP II trial (De Backer et al., NEJM 2010) demonstrated that dopamine was associated with significantly more arrhythmic events and a trend toward higher mortality compared to norepinephrine. Surviving Sepsis Campaign (SSC 2021) recommends norepinephrine as the first-line vasopressor, reserving dopamine for patients with relative bradycardia and low tachyarrhythmia risk only.
Can vasopressors be given peripherally?
Vasopressors should be given via central venous access when possible. Norepinephrine, dopamine, and phenylephrine can cause tissue necrosis on extravasation. Short-duration peripheral administration (via large, proximal, well-functioning IV) may be acceptable as a temporising measure in life-threatening hypotension while central access is established — most guidelines now support this if monitored carefully.
What is the target MAP in septic shock?
The SSC recommends MAP ≥65 mmHg as the initial target in most patients with septic shock. In patients with pre-existing hypertension, chronic renal disease, or vasoconstrictive physiology, individual targets of 70–80 mmHg may improve outcomes. The 65PLUS trial (2020) showed no benefit from higher MAP targets (80–85 mmHg) in the general septic shock population.
What is epinephrine used for in emergency settings?
Epinephrine 1 mg IV is the first-line drug in cardiac arrest (every 3–5 minutes). In anaphylaxis, IM epinephrine 0.3–0.5 mg (0.3–0.5 mL of 1:1000) is the first-line treatment. IV epinephrine infusion (0.01–1 mcg/kg/min) is used for anaphylactic shock refractory to IM epinephrine and for severe cardiogenic shock or refractory vasodilatory shock.
What are the advantages of phenylephrine over norepinephrine?
Phenylephrine is a pure alpha-1 adrenergic agonist with no beta activity, making it useful when tachycardia is undesirable (e.g., severe aortic stenosis, septal hypertrophic obstructive cardiomyopathy, certain arrhythmias). It has no direct inotropic effect and may reduce cardiac output — it should be avoided in cardiogenic shock. Phenylephrine is also used in spinal anaesthesia-induced hypotension.
How do I safely wean vasopressors?
Vasopressor weaning should be gradual (25–50% dose reduction every 30–60 minutes), guided by haemodynamic response. Abrupt discontinuation causes rebound vasodilation and cardiovascular collapse. Wean the most recently added agent first (usually vasopressin before norepinephrine). Confirm resolution of the underlying shock state (lactate clearance, urine output, improving clinical picture) before initiating weaning.
Is there a maximum dose for vasopressors?
There are no absolute dose ceilings for vasopressors in refractory shock, but high doses (norepinephrine >0.5 mcg/kg/min, dopamine >20 mcg/kg/min) are associated with severe adverse effects including digital ischaemia, mesenteric ischaemia, and cardiac arrhythmias. In refractory shock despite high-dose catecholamines, additional agents (vasopressin, methylene blue, angiotensin II) or mechanical circulatory support should be considered.
What is catecholamine-induced cardiomyopathy?
Emergency Drug Drips is a specialized calculation tool designed to help users compute and analyze key metrics in the health and medical domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
Pro Tip
Prepare a bedside vasopressor dosing cheat-sheet for each patient specific to their weight and drug concentration. The most common ICU error with vasoactive infusions is a calculation mistake or pump programming error — double-checking rates with a second nurse and using institution-approved drug libraries in pump software prevents the majority of these errors.
Did you know?
Norepinephrine (noradrenaline) is not only a drug but also one of the body's primary fight-or-flight neurotransmitters, released from the adrenal medulla and sympathetic nerve terminals in response to physiological stress. In septic shock, patients may release extraordinary amounts of endogenous catecholamines — yet still require exogenous vasopressors because the vascular smooth muscle receptors become desensitised and downregulated over time.
References
- ›Surviving Sepsis Campaign Guidelines 2021 (Evans L et al.)
- ›De Backer D et al. — Dopamine vs Norepinephrine in Shock (NEJM 2010 SOAP-II trial)
- ›Russell JA et al. — Vasopressin vs Norepinephrine (VASST trial, NEJM 2008)
- ›Rhodes A et al. — Surviving Sepsis Campaign International Guidelines 2016
- ›FICM/ICS — Standards for the Care of Adult Patients with Invasive Mechanical Ventilation